Volume 15, Issue 1 (Iranian Journal of Breast Diseases 2022)                   ijbd 2022, 15(1): 59-70 | Back to browse issues page


XML Persian Abstract Print


1- Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
2- Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran & Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran , bayazidg@yahoo.com
Abstract:   (1690 Views)
Introduction: Metabolic syndrome or insulin resistance syndrome is described as abdominal obesity, dyslipidemia, fasting blood sugar, and high blood pressure. This study aimed to investigate the relationship between metabolic syndrome and breast cancer.
Methods: This case-control study was performed on 222 women with cancer and non-cancer (breast cancer) (111 participants in each group) referred to Tohid and Besat Hospital in Sanandaj in 2014.
Results: The results showed that the prevalence of metabolic syndrome in people with and without breast cancer was 85 (76.6%) and 60 (54.1%), respectively, which was statistically significant.
Conclusion: The results showed that the criteria for defining metabolic syndrome increase cancer risk, especially breast cancer in women, and measures should be taken to reduce these risks in high-risk groups.
Full-Text [PDF 990 kb]   (591 Downloads)    
Conclusion: The results showed that the criteria for defining metabolic syndrome increase cancer risk, especially breast cancer in women, and measures should be taken to reduce these risks in high-risk groups.

Type of Study: Research |
Received: 2021/09/20 | Accepted: 2021/12/27 | Published: 2022/04/30

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.